196 related articles for article (PubMed ID: 31399069)
21. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G
Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789
[TBL] [Abstract][Full Text] [Related]
22. Asymptomatic progressive multifocal leukoencephalopathy during natalizumab therapy with treatment.
Fabis-Pedrini MJ; Xu W; Burton J; Carroll WM; Kermode AG
J Clin Neurosci; 2016 Mar; 25():145-7. PubMed ID: 26541323
[TBL] [Abstract][Full Text] [Related]
23. [Treatment of relapsing-remitting multiple sclerosis with fingolimod in routine clinical practice].
Alcala-Vicente C; Perez-Miralles FC; Gascon-Gimenez F; Bosca-Blasco I; Navarre-Gimeno A; Coret-Ferrer F; Casanova-Estruch B
Rev Neurol; 2017 May; 64(10):445-453. PubMed ID: 28497440
[TBL] [Abstract][Full Text] [Related]
24. Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab.
Blinkenberg M; Sellebjerg F; Leffers AM; Madsen CG; Sørensen PS
Mult Scler; 2013 Aug; 19(9):1226-9. PubMed ID: 23508652
[TBL] [Abstract][Full Text] [Related]
25. Comment on 'Fingolimod to treat severe MS after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?' Maillart et al.
Tur C; Montalban X
Mult Scler; 2014 Apr; 20(4):510-1. PubMed ID: 24468818
[No Abstract] [Full Text] [Related]
26. Severe Progressive Multifocal Leukoencephalopathy (PML) and Spontaneous Immune Reconstitution Inflammatory Syndrome (IRIS) in an Immunocompetent Patient.
Krey L; Raab P; Sherzay R; Berding G; Stoll M; Stangel M; Wegner F
Front Immunol; 2019; 10():1188. PubMed ID: 31191548
[No Abstract] [Full Text] [Related]
27. Halting progressive multifocal leukoencephalopathy with pembrolizumab: the case of a patient with multiple sclerosis under fingolimod.
Jeantin L; Shor N; Pallix-Guyot M; Roos-Weil D; Bellanger A; Le Garff-Tavernier M; Papeix C; Weiss N; Pourcher V
J Neurol; 2024 Feb; 271(2):729-732. PubMed ID: 37910249
[No Abstract] [Full Text] [Related]
28. Assessing PML risk under immunotherapy: if all you have is a hammer, everything looks like a nail.
Van Schependom J; Gielen J; Laton J; Nagels G
Mult Scler; 2016 Mar; 22(3):389-92. PubMed ID: 26199353
[TBL] [Abstract][Full Text] [Related]
29. Progressive Multifocal Leukoencephalopathy and Immune Reconstitution Inflammatory Syndrome after Discontinuation of Fingolimod.
Piñar Morales R; Carrasco Garcia M; Gutierrez-Rojas L; Barrero Hernández FJ
Case Rep Neurol; 2022; 14(1):38-43. PubMed ID: 35350291
[TBL] [Abstract][Full Text] [Related]
30. [Progressive multifocal leukoencephalopathy associated to natalizumab: the importance of magnetic resonance imaging in its early diagnosis].
Martí G; Río J; Rovira À; Auger C; Tintoré M; Sastre-Garriga J; Vidal A; Castilló J; Montalban X
Rev Neurol; 2015 Feb; 60(4):164-8. PubMed ID: 25670046
[TBL] [Abstract][Full Text] [Related]
31. A case of immune reconstitution syndrome complicating progressive multifocal leukoencephalopathy after kidney transplant: Clinical, pathological, and radiographic features.
Jackowiak E; Shah N; Chen H; Ojha A; Doyle J; Shepler A; Bogdanovich T; Silveira FP; Haidar G
Transpl Infect Dis; 2019 Oct; 21(5):e13162. PubMed ID: 31419376
[TBL] [Abstract][Full Text] [Related]
32. Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
Faulkner M
Expert Opin Drug Saf; 2015; 14(11):1737-48. PubMed ID: 26394704
[TBL] [Abstract][Full Text] [Related]
33. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab.
Kleinschmidt-DeMasters BK; Miravalle A; Schowinsky J; Corboy J; Vollmer T
J Neuropathol Exp Neurol; 2012 Jul; 71(7):604-17. PubMed ID: 22710964
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients.
Wattjes MP; Wijburg MT; Vennegoor A; Witte BI; Roosendaal SD; Sanchez E; Liu Y; Martins Jarnalo CO; Richert ND; Uitdehaag BM; Barkhof F; Killestein J
Mult Scler; 2016 Aug; 22(9):1174-83. PubMed ID: 26564995
[TBL] [Abstract][Full Text] [Related]
35. [MRI alterations in immunomodulation].
Guggenberger K; Urbach H
Nervenarzt; 2018 Aug; 89(8):945-957. PubMed ID: 30030575
[TBL] [Abstract][Full Text] [Related]
36. Progressive multifocal leukoencephalopathy after fingolimod treatment.
Berger JR; Cree BA; Greenberg B; Hemmer B; Ward BJ; Dong VM; Merschhemke M
Neurology; 2018 May; 90(20):e1815-e1821. PubMed ID: 29669908
[TBL] [Abstract][Full Text] [Related]
37. Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications.
Igra MS; Paling D; Wattjes MP; Connolly DJA; Hoggard N
Br J Radiol; 2017 Jun; 90(1074):20160721. PubMed ID: 28362522
[TBL] [Abstract][Full Text] [Related]
38. PML: The Dark Side of Immunotherapy in Multiple Sclerosis.
Warnke C; Olsson T; Hartung HP
Trends Pharmacol Sci; 2015 Dec; 36(12):799-801. PubMed ID: 26497099
[TBL] [Abstract][Full Text] [Related]
39. Effect of dosage reduction on peripheral blood lymphocyte count in patients with multiple sclerosis receiving long-term fingolimod therapy.
Takahashi K
J Clin Neurosci; 2019 May; 63():91-94. PubMed ID: 30772201
[TBL] [Abstract][Full Text] [Related]
40. [Differential diagnosis of immune reconstitution inflammatory syndrome and progressive multifocal leukoencephalopathy after natalizumab withdrawal].
Yakushina TI; Yakushin DM; Shtang IO
Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(3):116-121. PubMed ID: 36946407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]